Security key
03969K108
Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT)
CUSIP: 03969K108
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 123,454,843
- Total 13F shares
- 128,962,296
- Share change
- +2,623,889
- Total reported value
- $3,744,475,286
- Put/Call ratio
- 15%
- Price per share
- $29.04
- Number of holders
- 280
- Value change
- +$103,845,955
- Number of buys
- 168
- Number of sells
- 102
Report period
Q4 2025
Institutions
280
Top holders
10
ARQT full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Arcutis Biotherapeutics, Inc. SEC filings
Arcutis Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 03969K108
Recent filing periods:
Top shareholders of ARQT - Arcutis Biotherapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Frazier Life Sciences VIII, L.P. |
13D/G
3/4/5
|
Patrick J. Heron · 10%+ Owner |
7.5%
|
8,943,712
|
$130,399,321 | $0 | 18 Aug 2025 | |
| Rubric Capital Management LP |
13D/G
13F
|
Company |
6.8%
|
8,271,577
|
$239,875,733 | $0 | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
13D/G
|
Company |
4.2%
from 13D/G
|
5,298,754
|
$99,881,513 | — | 30 Sep 2025 | |
| Halley E. Gilbert |
3/4/5
|
Director |
0.02%
|
22,123
|
$609,468 | -$455,442 | 20 Nov 2025 | |
| Neha Krishnamohan |
3/4/5
|
Director |
0.02%
|
22,123
|
$517,014 | -$939,494 | 13 Nov 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
9.9%
|
12,254,119
|
$230,990,144 | — | 30 Sep 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
8.5%
|
10,478,000
|
$197,510,300 | — | 30 Sep 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
8%
|
9,874,511
|
$186,134,532 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.9%
|
8,573,995
|
$161,619,806 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.8%
|
7,146,090
|
$134,703,797 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.8%
|
4,641,315
|
$87,488,788 | — | 30 Sep 2025 | |
| GILDER GAGNON HOWE & CO LLC |
13F
|
Company |
3.6%
|
4,429,108
|
$83,488,686 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
3.5%
|
4,276,394
|
$80,610,030 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
2.4%
|
2,948,438
|
$55,578,057 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,606,465
|
$49,139,527 | — | 30 Sep 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1.9%
|
2,398,031
|
$45,178,904 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.9%
|
2,311,019
|
$43,562,708 | — | 30 Sep 2025 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
1.7%
|
2,120,508
|
$39,971,576 | — | 30 Sep 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.7%
|
2,118,713
|
$39,937,740 | — | 30 Sep 2025 | |
| Perpetual Ltd |
13F
|
Company |
1.6%
|
2,024,606
|
$38,163,823 | — | 30 Sep 2025 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
1.6%
|
1,993,055
|
$37,569,087 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.5%
|
1,804,988
|
$34,024,024 | — | 30 Sep 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
1.3%
|
1,662,470
|
$31,337,590 | — | 30 Sep 2025 | |
| Nuveen, LLC |
13F
|
Company |
1.1%
|
1,370,356
|
$25,831,211 | — | 30 Sep 2025 | |
| GW&K Investment Management, LLC |
13F
|
Company |
0.95%
|
1,172,041
|
$22,093,000 | — | 30 Sep 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.89%
|
1,097,004
|
$20,678,525 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.81%
|
999,434
|
$18,839,331 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.76%
|
940,202
|
$17,722,808 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.72%
|
889,285
|
$16,763,022 | — | 30 Sep 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.68%
|
833,490
|
$15,711,286 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.66%
|
814,567
|
$15,354,588 | — | 30 Sep 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.63%
|
778,044
|
$14,666,129 | — | 30 Sep 2025 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.63%
|
775,000
|
$14,608,750 | — | 30 Sep 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.62%
|
759,573
|
$14,317,951 | — | 30 Sep 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.55%
|
675,034
|
$12,724,391 | — | 30 Sep 2025 | |
| JUPITER ASSET MANAGEMENT LTD |
13F
|
Company |
0.53%
|
659,331
|
$12,428,390 | — | 30 Sep 2025 | |
| FISHMAN JAY A LTD/MI |
13F
|
Company |
0.46%
|
565,650
|
$10,662,503 | — | 30 Sep 2025 | |
| Tejara Capital Ltd |
13F
|
Company |
0.42%
|
520,503
|
$9,811,482 | — | 30 Sep 2025 | |
| MYDA Advisors LLC |
13F
|
Company |
0.38%
|
470,000
|
$8,859,500 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.36%
|
441,315
|
$8,318,787 | — | 30 Sep 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.33%
|
411,893
|
$7,764,183 | — | 30 Sep 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.31%
|
377,528
|
$7,116,403 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.29%
|
360,770
|
$6,800,515 | — | 30 Sep 2025 | |
| PFM Health Sciences, LP |
13F
|
Company |
0.29%
|
360,460
|
$6,794,671 | — | 30 Sep 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
0.29%
|
353,644
|
$6,666,189 | — | 30 Sep 2025 | |
| Jump Financial, LLC |
13F
|
Company |
0.28%
|
350,485
|
$6,606,642 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.26%
|
325,968
|
$6,144,497 | — | 30 Sep 2025 | |
| Simplify Asset Management Inc. |
13F
|
Company |
0.26%
|
317,997
|
$5,994,243 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.25%
|
314,619
|
$5,930,568 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.25%
|
310,620
|
$5,855,188 | — | 30 Sep 2025 |
Institutional Holders of Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT) as of Q4 2025
As of 31 Dec 2025,
Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT) was held by
280 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
128,962,296 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, Frazier Life Sciences Management, L.P., BlackRock, Inc., Rubric Capital Management LP, VANGUARD GROUP INC, JENNISON ASSOCIATES LLC, Polar Capital Holdings Plc, STATE STREET CORP, GILDER GAGNON HOWE & CO LLC, and MORGAN STANLEY.
This page lists
280
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
235
Q4 2025 holders
280
Holder diff
45
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.